Clinical trials: Hematologic Neoplasms
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Pediatric ALL
Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures
- Trial name
- NCT04851717
- Testing
- Remimazolam
- Where
- 8 sites in United States, Denmark
- Volunteers
- 100 people
- Sponsor
- Acacia Pharma Ltd
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Increasing Knowledge and Interest in Cancer Clinical Trials
This trial investigates how well a video-based clinical trial education session works in increasing knowledge and interest in cancer clinical trials among individuals in the metropolitan Detroit region of the Karmanos Cancer…
- Trial name
- NCT06501040
- Testing
- Web-based Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Hayley Thompson
Acute Myeloid Leukemia (AML)
Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia
The goal of this clinical trial is to test a way of delivering supportive care to adults 60 years and older who are starting venetoclax-based treatment for newly diagnosed acute myeloid leukemia (AML).
- Trial name
- ACTIVE DEFAULT (NCT07777471)
- Testing
- Active Default
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
AML - Acute Myeloid Leukemia
Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML).
- Trial name
- COSMOS-Avatar (NCT06782971)
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Clinical Hub for Interventional Research (CHOIR)
Hematopoietic/Lymphoid Cancer, Acute Myeloid Leukemia
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn about the safety and tolerability of 3 different doses of CD33-CAR-T…
- Trial name
- NCT03126864
- Testing
- Leukapheresis, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
- Trial name
- NCT05506332
- Testing
- Venetoclax, 6-mercaptopurine
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Leukemia, Lymphocytic, Chronic, B-Cell
Phase II Trial GA101 Inbrutinib B CLL
Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months / Study Part 1: All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days Study Part 2: After evaluation at D1 of…
- Trial name
- ICLL07GAI (NCT02666898)
- Testing
- GA101, Ibrutinib, Cyclophosphamide
- Where
- France
- Volunteers
- 135 people
- Sponsor
- French Innovative Leukemia Organisation
Chronic Lymphoid Leukemia
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
Open label, single arm, multicenter phase II trial.
- Trial name
- NCT03766763
- Testing
- Venetoclax
- Where
- 23 sites in France
- Volunteers
- 82 people
- Sponsor
- French Innovative Leukemia Organisation
Multiple Myeloma
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by…
- Trial name
- CARTITUDE-5 (NCT04923893)
- Testing
- Bortezomib, Dexamethasone, Lenalidomide
- Where
- 136 sites in United States, Argentina and 24 more
- Volunteers
- 743 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Lymphoid, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia
The study objectives are to evaluate the safety and efficacy of the oral administration of lenalidomide in combination with dexamethasone in the treatment of adult patients with refractory or relapsed non-Ph+ B-cell lineage acute…
- Trial name
- RV-405 LAL (NCT01116193)
- Testing
- Lenalidomide plus dexamethasone
- Where
- 4 sites in France
- Volunteers
- 10 people
- Sponsor
- Institut de Cancérologie de la Loire
Preleukemia, Myeloproliferative Disorders
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
This is a clinical research study designed to evaluate whether the administration of a vaccine to patients after transplant consisting of a minor histocompatibility antigen (mHag peptide) mixed with G-CSF (a drug intended to…
- Conditions
- Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma
- Trial name
- NCT00943293
- Testing
- Fludarabine, Melphalan, Campath
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult
Natural Killer-cell Therapy for Acute Myeloid Leukemia
This study investigates an innovative treatment for relapsed or refractory acute myeloid leukemia exploiting administration of ex vivo-generated allogeneic natural killer (NK) cells with preceding non-myeloablative conditioning…
- Trial name
- NK4AML (NCT04347616)
- Testing
- UCB-NK cells, IL-2
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- Radboud University Medical Center
Hematologic Malignancy
A Phase I Study of BR108 in Hematological Malignancies
A Phase I study of BR108 in hematological malignancies
- Trial name
- NCT06018506
- Testing
- BR108 injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Waldenstrom Macroglobulinemia
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia.
- Trial name
- BRAWM (NCT04624906)
- Testing
- Acalabrutinib, Bendamustine, Rituximab
- Where
- 9 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Sunnybrook Health Sciences Centre
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Sleep Apnea in Patients With MGUS and MM
This study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), with and without sleep apnea, who are providing bone marrow specimens.
- Trial name
- NCT04114084
- Testing
- Bone Marrow Aspirate and Biopsy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Michael Tomasson
Chronic Leukemia, Acute Leukemia
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at…
- Conditions
- Chronic Leukemia, Acute Leukemia, Myeloproliferative Disorders, Lymphoproliferative Disorders
- Trial name
- NCT07445984
- Testing
- Genetic, molecular and/or omics analyses
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone…
- Trial name
- DREAMM 7 (NCT04246047)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 69 sites in United States, Australia and 11 more
- Volunteers
- 494 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia/Lymphoma
CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
The objective of this study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
- Trial name
- NCT07106749
- Testing
- CD180 CART
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China